AQEMIA

AQEMIA is a private, preclinical-stage biotech leveraging a unique physics-first AI platform to accelerate and scale the invention of new medicines. Its core technology, rooted in over 12 years of academic research in quantum physics, enables the rapid and accurate prediction of molecular interactions, allowing generative AI to explore novel chemical spaces without historical bias. The company, co-founded by a quantum physicist and a former BCG principal, operates a platform-based business model and is currently pre-revenue, focusing on building its internal pipeline and potential partnerships.

QEMI platform combining proprietary fast-physics algorithms (for accurate, data-free binding affinity prediction) with generative AI for novel molecule design.

AQEMIA competes in the crowded AI drug discovery space against companies like Exscientia, Recursion, and Insilico Medicine. Its key differentiator is its foundational use of first-principles physics to avoid training data bias, a contrast to many competitors that rely heavily on historical biological and chemical data.